TORONTO, Sept. 22 /CNW/ - ARIUS Research Inc. ("ARIUS") (TSX: ARI),
announced today that Daniel S. Pereira, Ph.D., has joined ARIUS as Vice
President of Research.
Dr. Pereira comes to ARIUS after 8 years at ImClone Systems Incorporated
("Imclone") where he was Director of the Tumor Biology department. In his most
recent role at ImClone, Dr. Pereira directed antibody target identification
efforts, lead and authored a publication on the RON antibody project, and was
a member of the steering committee for the company's antibody projects.
"We are delighted to welcome Dr. Pereira to ARIUS as a senior member of
the management team," said Dr. David S. Young, President and Chief Scientific
Officer of ARIUS. "With his leadership and scientific insight we can look
forward to building new value into our pipeline and intellectual property
portfolio, which in turn will add value for partnerships and future deals."
Dr. Pereira brings extensive research experience in discovery,
characterization and development of anti-cancer antibodies. Reporting to Dr.
Young, he will manage a team of scientists and will be responsible for
continued innovation to ARIUS' FunctionFIRST Platform and pre-clinical
characterization of ARIUS' functional antibodies.
In 1994, Dr. Pereira received his doctorate from McMaster University
where he was a Doctoral Fellow of the Cancer Research Society of Canada. He
later joined Dr. John Dick's Laboratory at the University of Toronto as a
Terry Fox post-doctoral research fellow of the National Cancer Institute of
Canada. There he identified genetic factors related to leukemia and developed
in vitro and in vivo models for the study of the disease.
About ARIUS
ARIUS is a biotechnology company dedicated to personalizing cancer
therapy through the discovery and development of novel anticancer monoclonal
antibodies (MAbs). Established in 1999, ARIUS has built a proprietary
technology platform, FunctionFIRST(TM), that rapidly identifies powerful MAbs
targeting a variety of cancer indications. This antibody generation engine has
enabled ARIUS to assemble a growing pipeline, which is used for commercial
collaborations and in-house development. ARIUS has ongoing partnerships with
key biotechnology and drug development companies. The company is listed on the
TSX under the symbol "ARI".
Forward-Looking Statement
Certain statements in this news release constitute "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act
of 1995, which involve known and unknown risks, uncertainties and other
factors that may cause our actual results to be materially different from any
future results, performance or achievements expressed or implied by such
statements. Forward-looking statements in this release include, but are not
limited to, ARIUS successfully advancing its new product programs as well as
licensing opportunities. These statements are only predictions and actual
events or results may differ materially. Factors that could cause such actual
events or results expressed or implied by such forward-looking statements to
differ materially from any future results expressed or implied by such
statements include, but are not limited to: early stage of development;
technology and product development; dependence on and management of current
and future corporate collaborations; future capital needs; uncertainty of
additional funding; no assurance of market acceptance; dependence on
proprietary technology and uncertainty of patent protection; intense
competition; manufacturing and market uncertainties; and government
regulation. These and other factors are described in detail in ARIUS' Annual
Report, forthcoming news releases and other filings with Canadian securities
regulatory authorities available at www.sedar.com. Forward-looking statements
are based on our current expectations and ARIUS is not obligated to update
such information to reflect later events or developments.
%SEDAR: 00013708E
